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                                            ABSTRACT 
 
Background and objectives: To assess the efficacy of low molecular weight 
heparin in the management of generalized cutaneous lichen planus. 
Materials and methods: This is a one year open label prospective randomized 
study from July 2013 to June 2014. About 50 cases of generalized Cutaneous 
lichen planus willing to participate and follow up were included in the study. A 
brief and relevant medical history was taken during the initial visit and physical 
examination done to ensure that all relevant eligible criteria are met. Patients were 
given Injection Enoxaparin sodium 4 mg SC once weekly for 9 weeks and later 
followed up for 6 months. Efficacy is assessed by monitoring Itch severity score 
(ISS), DLQI, and nature of old and new lesions. 
Results: Clinical improvement noticed in the form of decrease in ISS with 
regression of cutaneous lesions within 1 to 3 weeks in 80 to 90% of cases. There 
was no occurrence of new lesions in 76% of cases. Improvement in DLQI was 
noticed in 80% and complete disappearance of itch in 66% of the patients at the 
end of the study. No adverse effects were observed. 
Conclusion: The rapid improvement and sustained remission in these cases 
implies that low molecular weight heparin could be a safe, effective and alternative 
monotherapy in the management of generalized cutaneous lichen planus. 
Key words: Lichen planus, Enoxaparin sodium, ISS, DLQI. 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
  
 
 
 
Lichen planus (LP) is a common and chronic inflammatory disease 
affecting the skin and mucosa that exhibits distinct morphologic and 
microscopic features.  It was first discovered in 1869 by Erasmus Wilson. 
The term Lichen is derived from Greek word (Leichen),which 
means tree moss. The word refers to a unique group of flowerless 
vegetations. The word ‘planus’ in Latin means ‘flat’. It is a self-limiting 
condition that most commonly affects middle-aged adults. It can involve 
glabrous skin, mucous membrane, hair and nails
(1)
. Oral lichen planus can 
occur without skin lesions or skin lesions may precede, follow or appear 
at the same time as those in the oral cavity. 
The classical cutaneous lesion of lichen planus is variable and is 
commonly a pruritic, polygonal, faintly erythematous to violaceous flat 
topped papules with flexor distribution. Less common variants include 
hypertrophic, atrophic, vesicular and bullous lesions. Isomorphic 
phenomenon is characteristic of this condition
(1)(5)
. Many agents have 
been implicated in the etiology. It is often associated with various 
autoimmune and liver disorders. Although spontaneous remission do 
occur in LP, the natural history is quite variable and depend on the site of 
involvement and clinical pattern
(43)
. 
                                     
 
 
 
Various treatment modalities exist ranging from topical to 
systemic therapy. Response rates vary in different individuals and with 
different subset of clinical lesions. Classical cutaneous lesions usually 
respond to existing therapy. Newer modalities of treatment do exist and 
these are tried either as second line therapy or for refractory lesions. 
Low dose of low molecular weight heparin (Enoxaparin) was first 
used by Hodak et al
(11)
 in 1988 at the dose of 3 mg in the management of 
lichen planus. There was regression with cutaneous lesions with no 
improvement in the oral lesions. 
Enoxaparin Sodium was used in cases of generalized cutaneous 
lichen planus in this study to determine it’s efficacy and also to use it as a 
alternative monotherapy in this condition. 
Oral lichen planus responds poorly to treatment. There are chances 
of transition to Squamous cell carcinoma with oral lesions especially the 
erosive(ulcerative) variant, the frequency being 0.8%
(72)
. 
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HISTORICAL ASPECTS 
Lichen planus was first discovered in 1869 by Erasmus Wilson. 
The dermatosis was earlier described by Hebra as ‘Leichen Ruber’(1). 
Louis Fredrick Wickham described the characteristic striae in 1895 and 
Graham Little described scalp involvement in lichen planus in 1919.The 
histological findings in lichen planus were defined in 1909 by Darier and 
attributed Wickham’s striae to an increase in granular layer(1)(6). 
The word “Lichen”is derived from Greek word ‘Leichen’, which 
means “to lick”. In Latin it denotes a kind of plant. This word is used as a 
noun in Greek and Latin to denote those symbiotic forms of life 
(combined growth of algae and fungus) that are now called lichens
(1)(3)
. 
Trautmann described the vesiculo-bullous form of lichen planus in 
the oral mucosa in 1911.Lichen planus has also been reported involving 
other mucous membranes. The occurrence of oral lesions in the absence 
of dermal lesions in lichen planus was first pointed out by Audry (1894). 
Hebra described the condition as Leichen ruber/ Lichen ruber 
planus.  
 
                      
 
 
 
Hallopeau (1887) and Darier (1892) considered it as a 
modification of Lichen sclerosus et atrophicus
(6)
 because of 
morphological similarity. 
Lichen planopilaris (Pringle,1895) and follicular lichen planus 
(Silver et al) are terms that describe association of lichen planus with 
cicatrical alopecia
(7)
. 
Thyresson and Meberger demonstrated colloid bodies at dermo-
epidermal junction and confirmed about it’s nature to degenerating 
epithelial cells. 
Pinkus and Mehregan (1969) proposed that damage to the basal 
cell layer as the basic histopathological finding
(9)
.Zaias described 
histology of nail lesions in lichen planus
(8)
. 
In 1989, Perforating variant of lichen planus (Hanav and Senegal) 
and Grinspan syndrome
(8)(13)
 that comprises a triad of lichen planus with 
hypertension and diabetes mellitus were described. 
Lichen planus-Lupus erythematosus overlap was described in 
1970. Pelisse at al described Vulvo-vaginal gingival syndrome in 1982
(10)
. 
                                    
 
 
 
Glickman (1964) suggested that pallor producing Wickham’s 
striae to the absence of capillaries in the center of the lesion. Ryan in 
1966 attributed violaceous hue to the radially arranged capillaries
(6)(9)
. 
Niles (1941) described actinic lichen planus
(8)
. 
Cribier et al described the male equivalent of Vulvo-vaginal 
gingival syndrome as Peno-genital syndrome in 1993. Association 
between lichen planus and hepatitis C infection was described in 1994. 
Hard and Humberg used penicillin for treating lichen planus 
(1954). Sehgal et al demonstrated efficacy of griseofulvin in 1971 and 
levamisole in 1978 in cases of recalcitrant lichen planus. Other drugs like 
dapsone, isotretinoin, phenytoin, cyclosporine and PUVA therapy have 
been tried with variable degrees of success in lichen planus
(8)
. 
 
 
 
 
                                         
 
 
 
EPIDEMIOLOGY 
Incidence: 
The exact incidence and prevalence of lichen planus are not 
known, but the overall prevalence is believed to be somewhat less than 
1% of general population. Lichen planus has a worldwide distribution 
with no racial predisposition. Estimates between 0.14% and 0.80% have 
been reported worldwide
(1)(8)
. 
Age: 
Females are usually affected in their fifties and sixties, whereas 
males develop lichen planus at an earlier age.  The disease is less 
common in very young and the elderly
(1)(8)
. 
Sex: No sexual predisposition is evident(1)(8). 
Seasonal variation: 
The development of lichen planus may be affected by seasonal or 
environmental factors.  An increased incidence in December and January 
or from January to July has been reported
(1)(8)
. 
                                             
 
 
 
Triggering factors:  
Sunlight, trauma, friction. 
Genetic factors: 
An increase in frequency of HLA-B7, -AW19,-B18 and CW8 
haplotypes were noted in familial lichen planus.HLA-A3, -A5, -A28, -B8, 
-B16 and –BW35were noted in non-familial lichen planus(1). 
HLA-B8 was common in patients of oral LP and HLA-BW35 with 
cutaneous lichen planus
(1)(15)
. 
ETIOPATHOGENESIS: 
It is evident that immunologic mechanisms almost certainly 
mediate the development of lichen planus. Humoral immunity most likely 
is a secondary response in the immuno-pathogenesis. Cell-mediated 
immunity plays a major role in triggering the clinical expression of the 
disease. 
Both CD4+ and CD8+ cells are found in lesional skin of lichen 
planus. The majority of lymphocytes in the infiltrate of lichen planus are 
CD8+ and CD45RO (memory) positive cells
(1)(8)
. 
 
 
 
                                      
These cells are considered responsible for the development of the most 
characteristic changes observed in lichenoid reactions, namely, 
apoptosis
(1)(8)
. 
The epithelial lymphocyte interaction can be divided into three 
major stages: Antigen recognition, Lymphocyte activation, and 
Keratinocyte apoptosis
(1)
. 
Lichen Planus-Specific Antigen Recognition: 
Majority of the T cells in the infiltrate of lichen planus are 
activated CD8+ cytotoxic lymphocytes. Evidence suggests that CD8+ 
lesional Tcells (within epithelium and adjacent to basal keratinocytes) 
recognize LP specific antigen associated with (MHC) class I on lesional 
keratinocytes. The antigen may be autoreactive peptide suggesting that 
LP may be an autoimmune disease. 
Alternatively it may represent an exogenous antigen such as 
altered protein, drug, contact allergen, dental amalgam, viral infectious 
agents or unidentified immunogenic target
(1)
. The role of T helper cells 
(CD4) in the etiopathogenesis of LP is not fully understood. These cells 
may become activated via antigen-presenting cells such as Langerhans 
 
 
 
cells in association with Major histocompatibility complex (MHC) class 
II and specific cytokines
(1)
. 
T helper (CD4) cells may also propagate CD8+ cytotoxic 
lymphocytes through cellular cooperation and release of cytokines. 
The exact nature of antigenic stimulation is not known. Contact 
sensitizers such as metals which may act as haptens elicit an 
immunogenic response. 
Low-grade chronic exposure to mercury and other metals 
stimulate a lymphocytic reaction manifesting as LP. The role of 
infections or microorganisms: Syphilis, Herpes simplex virus 2, HIV, 
amoebiasis, chronic infections, hepatitis virus, helicobacter pylori and 
human papilloma virus in the development of LP is still not clear
(1)
. 
Cytotoxic lymphocyte activation: 
Activated T-lymphocytes by TH1, TH2 and cytotoxic-suppressor 
cells, release soluble mediators: Interleukin, IL-2, IL-4, IL-10, Interferon- 
(INF)-gamma, Tumor necrosis factor (TNF)-alpha,that attract 
lymphocytes and regulate their activities in epithelium. Both pro and anti-
inflammatory cytokines are generated simultaneously. The balance 
 
 
 
between lymphocytic activation and down regulation determines clinical 
behaviour of the disease.  
Interferon gamma produced by T helper cells during the antigen 
recognition stage, induces keratinocytes to produce lymphotoxin-alpha 
and TNF-alpha and to upregulate MHC-II thus increasing interactions 
with helper T cells
(1)(8)
. 
Interferon gamma also up-regulates the expression of intercellular 
adhesion molecule (ICAM)-I and vascular cell adhesion molecule 
(VCAM)-I by basal keratinocytes, Langerhans cells, and other 
macrophage-dendritic cells
(1)
. 
Laminin-5 and collagen types IV and VII, are increased in lesional 
LP and serve as ligands for β1-intergrins on the surface of lymphocytes, 
thus allowing for enhanced association of lymphocytes with the basement 
membrane
(1)
 
This close interaction between lymphocytes and basement 
membrane, targets metalloproteinases to alter extracellular matrix 
proteins and integrins, thus causing apoptosis, BM disruption, 
reduplication and subepidermal cleft formation. 
 
 
 
 
 
Keratinocyte apoptosis
(1)(8)
: 
The exact mechanisms that trigger apoptosis are not known. 
Possible mechanisms are- 
1) T cell secreted TNF-alpha binding to TNF-alpha R1 receptor 
on keratinocyte surface. 
2) T cell surface CD95L binding CD95 on keratinocyte. 
3)T cell secreted granzyme-B entering keratinocyte via perforin-
induced membrane pores. 
Basement membrane disruption may trigger apoptosis through the 
loss of basement membrane-derived cell survival signals that normally 
prevents the onset of apoptosis mediated by recruited lymphocytes. 
 
 
 
 
 
 
 
CLINICAL FEATURES 
Lichen planus affects the skin, mucous membranes, hair and 
nails
(1)
. 
The classical cutaneous lesions are flat-topped, faintly 
erythematous to violaceous polygonal pruritic papules of varying sizes, 
may be asymptomatic in some.  A thin, transparent and adherent scale 
may be present over the papules. 
Fine, whitish puncta or reticulated networks referred to as 
“Wickham’s striae”, are present over the surface of many papules, which 
are easily observed after placing mineral or immersion oil over the 
lesions
(1)(8)
. 
Lesions are classically distributed symmetrically and bilaterally 
over flexural areas of wrists, arms, legs and lower back
(1)(8)
.   
In active disease, scratching, injury or trauma may induce an 
isomorphic response (KOEBNER PHENOMENON). The lesions usually 
heal with hyperpigmentation
(1)(15)
. 
 
 
 
 
 
Classification of Lichen Planus Variants
(1)
: 
Configuration 
Annular 
Linear 
Morphology of lesion 
Hypertrophic 
Atrophic 
Vesiculobullous 
Erosive/Ulcerative 
Follicular 
Actinic 
Lichen planus pigmentosus 
Other forms: Perforating or Guttate. 
Sites of involvement 
Palms and Soles 
Mucous membrane 
Nails and Scalp 
 
 
 
 
Special forms 
Drug induced (Lichenoid drug eruptions) 
Lichen planus-Lupus erythematosus overlap 
Lichen planus pemphigoides 
Keratosis lichenoides chronica 
Lichen planus and malignant transformation 
Lichenoid reaction of graft versus host disease 
Lichenoid keratosis 
Lichenoid dermatitis 
CONFIGURATION 
Annular Lichen Planus 
They occur approximately in 10% of cases and commonly develop 
as arcuate grouping of individual papules that develop rings or peripheral 
extension of clustered papules with central clearing. Characteristically 
seen over penis and scrotum and more commonly in blacks
(1)(16)
. 
 
 
 
 
Linear Lichen Planus 
Linear lesions as a result of koebner’s phenomenon are frequently 
found in LP but isolated linear lesions, usually made up of small papules 
in close apposition extending the whole length of a limb may occur. This 
type is usually seen in childhood. This variant must be distinguished from 
linear naevi and other dermatoses with linear variants. A zosteriform 
pattern of LP has also been described and LP can develop in the site of 
healed herpes zoster.  Multiple linear LP was documented in a human 
immunodeficiency virus (HIV) patient have been reported
(1)(15)
. 
MORPHOLOGY OF LESION: 
Hypertrophic Lichen Planus (LP Verrucosus) 
 These lesions are usually confined to the extremities, especially 
shins and interphalangeal joints and tend to be most pruritic variant. 
Lesions are thickened and elevated, purplish or reddish-brown in colour, 
hyperkeratotic with occasional verrucous plaque. The lesions heal with 
atrophic scar or hyper-or hypopigmentation. Chronic venous 
insufficiency is commonly present
(8)(15)
. 
 
 
 
 
Atrophic Lichen Planus: 
 This variant is rare and is characterized by few well-demarcated, 
white-bluish papules and plaques with central superficial atrophy. 
Commonly seen on lower extremities and trunk
(1)(15)
. 
Vesiculo-bullous Lichen Planus 
Two types are seen: 
a) Bullous lichen planus. 
b) Lichen planus pemphigoides 
Bullous Lichen Planus: 
Rare variant. Characterized by development of vesicles and bullae 
on pre-existing lesions of lichen planus
(1)(8)
. 
Lichen planus pemphigoides: 
This is a controversial entity with co-existence of lichen planus and 
bullous pemphigoid. Clinically, it consists of bullae on lesional and non-
lesional skin, often on the extremities.  These lesions can appear during 
flare-up of disease and may be associated with mild constitutional 
symptoms
(1)(8)
. Histologically, the typical changes of LP are seen along 
with sub-epidermal separation
(1)
. 
 
 
 
Erosive and Ulcerative Lichen Planus 
This rare variant has been described in oral cavity and the soles.  
Characterized by painful bullae and ulceration of the feet. Permanent loss 
of toe nails and cicatricial alopecia of scalp are common. Progression to 
squamous cell carcinoma has been reported in few cases of chronic 
ulcerative lesions of LP. The rare associations of erosive lichen planus are 
Castleman’s lymph node hyperplasia and malignant lymphoma(1)(8). 
Follicular Lichen Planus (Lichen Planopilaris, Lichen planus 
acuminatus, Peripilaris) 
This form may occur alone or in association with other forms of 
lichen planus. Keratotic follicular papules are present commonly over 
trunk, proximal extremities, may affect scalp by producing cicatricial 
alopecia. The triad of follicular lichen planus of skin with cicatrical 
alopecia of scalp and non-scarring alopecia of axilla and pubic area is 
known as Graham Little-Piccardi-Lasseuer Syndrome
(1)(8)
. 
Other variants of follicular LP include the Pseudopelade of Brocq, 
lichen planus follicularis tumidus form, post-menopausal frontal fibrosing 
alopecia and Lichen planoporitis
(1)(8)(10)
. 
 
 
 
 
 
Actinic Lichen Planus: 
This variant is also known as lichen planus subtropicus, summer time 
actinic lichenoid eruptions, lichen planus actinicus and lichenoid 
melanodermatosis. It is more common in Middle-East countries in the 
spring and summer. Lesions are limited to sun-exposed areas and are 
hyperpigmented with violaceous-brown colour and a thread, rolled edge 
showing well-defined borders with minimal pruritus and scaling
(1)(8)(13)
. 
Lichen Planus Pigmentosus: 
This is a pigmentary disorder, which may not be associated with 
typical LP papules. It is an uncommon variant and is characterized by 
hyperpigmented, dark-brown macules in sun-exposed areas and flexural 
folds
(1)(15)
. 
The mucous membranes, palms and soles are never involved. 
Erythema dyschromicum perstans (ashy dermatosis) that occurs in sun-
exposed areas bears similarity to this form of LP
(1)(8)
. 
 
 
 
 
 
Other Variants 
Guttate Lichen Planus 
It is characterized by widely scattered discrete lesions that seldom 
become chronic
(1)
. 
Exfoliative and Exanthematous forms 
These are very rare and may represent manifestations of lichenoid 
drug reactions
(1)
. 
Invisible Lichen Planus 
Lesions that are not perceptible with visible light illumination but 
become apparent with Wood’s lamp examination. Pruritus is present and 
this entity may be a minimal variant of lichen planus “invisible de 
Gougerot”(1)(8). 
SITE OF INVOLVEMENT 
Palmo-plantar Lichen Planus 
This acral, localized variant is rare. Characteristic lesions are very 
pruriginous, erythematous, scaly plaques with or without hyperkeratosis 
and are often seen on internal plantar arch. Yellowish, compact keratotic 
 
 
 
papules or papulonodules are seen on the lateral margins of the fingers 
and hand surfaces. They appear like callosities with an inflammatory, 
erythematous halo
(1)
. 
Mucosal lichen planus 
Lichen planus involves mucosal surfaces of mouth, vagina, 
esophagus, conjunctiva, urethra, anus, nose and larynx. Its prevalence is 
approximately 1% of adult population. It may be the only manifestation 
in 20-30% of patients
(1)(8)
. 
Oral Lichen Planus 
Oral lichen planus affects primarily middle aged adults and the 
prevalence is greater among women. Children are rarely affected. 30% to 
50% of patients with oral lichen planus also have cutaneous involvement. 
Most common sites include posterior buccal mucosa, tongue, gingiva, 
retromolar area, vestibule, palate, floor of mouth and lips
(1)(8)
. 
The World Health Organisation recognizes different forms of Oral 
Lichen Planus.  
(1) Reticular type 
(2) Erosive type 
 
 
 
(3) Plaque type 
(4) Atrophic type 
(5) Papular type 
(6) Bullous type 
Reticular type is the commonest presentation. It presents as interlacing 
white keratotic lines, also known as Honiton lace or Wickham’s striae. 
The striae are typically located bilaterally on the buccal mucosa, 
mucobuccal fold, gingival and less commonly the tongue, palate and 
lips
(1)(8)
. This type is usually asymptomatic. 
Erosive type is the second most common type of oral LP. It presents as a 
mix of erythematous and ulcerated areas surrounded by finely radiating 
keratotic striae. The erosion may be covered by a pseudomembrane. 
 Patients present with symptoms ranging from episodic pain to 
severe discomfort. The triad of erosive or desquamative lichen planus 
involving vulva, vagina and gingiva is known as Vulvo-Vaginal-Gingival 
Syndrome. Malignant transformation is common with this variant. 
 
 
 
Plaque type appears as a multiple, diffuse, raised white plaques 
commonly over buccal mucosa and tongue. This type of lichen planus is 
usually asymptomatic
(1)(8)
. 
Atrophic type presents as diffuse, erythematous patches surrounded by 
fine white striae. This can cause severe discomfort and burning sensation. 
Papular type of lichen planus is rare and it consists of small whitish 
papules, about 0.5 mm in diameter. They may also precede Wickham’s 
striae and they are usually asymptomatic. 
Bullous type is the least frequent form of oral lichen planus. The lesion 
appears as vesicles or bullae of variable size, that easily bursts leaving 
behind painful erosions.  
 It occurs mainly in the buccal mucosa, in particular in the area next 
to the second and third molar teeth. 
 70% of patients with cutaneous lichen planus develop oral lichen 
planus. Lichen planus can involve eyelids and conjunctiva also. It causes 
a foreign body sensation. They can be seen as fine, white lacy pattern in 
the tarsal conjunctiva. Rarely, Keratoconjunctivitis sicca may be seen. 
Inflammatory meatal fibrosing otitis can be seen in the ears. 
 
 
 
 
Genital Lichen planus: 
 Involvement of genitalia with cutaneous LP has been 
reported in 25% of men with typical lesions. They present with pruritus 
and burning sensation. Lesions consist of violaceous papules, commonly 
on glans penis. Annular lesions are frequently reported on the scrotum. 
Female genital involvement consists of patches of leukoplakia or 
erythroplakia, sometimes with erosions and generalized desquamative 
vaginitis. Anal lesions of mucosal lichen planus present with 
leukokeratosis, hyperkeratosis, fissuring and erosions
(1)(8)
. 
Lichen planus of nails 
 Nail involvement occurs in 10% to 15% of patients. Usually only a 
few finger nails or toe-nails are involved. Thinning, longitudinal ridging 
and dorsal slitting of nail plate (Onychoschizia) are the most common 
findings. Onycholysis, longitudinal striations (Onychorrhexis), subungual 
hyperkeratosis or even absence (anonychia) of nail plate can also be seen. 
Twenty-nail dystrophy (Trachyonychia) may be an isolated 
finding. Pterygium or forward growth of the eponychium with adherence 
to the proximal nail plate is a classical nail finding in lichen planus of the 
nail.  
 
 
 
 Pup-tent or tenting sign is observed as a result of nail bed 
involvement that elevates the nail plate and may cause longitudinal 
splitting
(1)(8)(15)
. 
Lichen planus of scalp 
 Lichen planus affects the scalp. Typically individual keratotic 
follicular papules that coalesce and merge over the scalp to form patches 
are seen, affecting women more than men.  Patients present with unifocal 
or multifocal hair loss that may be extensive and involve the entire scalp. 
Perifollicular erythema and acuminate keratotic plugs are characteristic 
features. End-stage disease is characterized by scarring alopecia that has 
led to the use of several clinical terms describing the entity like lichen 
planopilaris, folliculitis decalvans et atrophicus, lichen spinulosus et 
folliculitis decalvans and Graham-Little Syndrome
(1)
. 
Inverse lichen planus 
It is a rare variant characterized by red-brownish, discrete papules 
and nodules occurring in flexures like the axillae, groins, inframammary 
region and less likely, popliteal and antecubital area. Erosive flexural LP 
has also been reported
(1)(8)
. 
 
 
 
 
SPECIAL FORMS OF LP 
Lichenoid eruptions or Drug-induced Lichen planus:  
It is a group of cutaneous reactions identical or similar to lichen 
planus. Lichenoid drug eruptions develop after contact, ingestion, or 
inhalation of certain chemicals. The eruptions usually appear 
symmetrically on the trunk and extremities, with pattern restricted to 
photo distributed areas. Mucosal involvement is less common
(1)
. 
Lichen planus-Lupus erythematosus overlap syndrome 
It is an overlap between LP and Lupus erythematosus. Atrophic 
plaques and patches with hypopigmented and a livid red to blue-violet 
colour with telengiectasiae and minimal scaling are characteristic. 
Lesions are most commonly seen on the extremities.  Some patients may 
progress to SLE.  In others, laboratory evaluation may reveal only a 
weakly positive antinuclear antibody. This disease variant is 
characterized by a prolonged course and lack of response to 
treatment
(1)(8)
.Histologically, features of LP and LE are usually seen in the 
same biopsy specimen. On DIF, features of LP with linear to granular 
deposits of IgM and C3 are seen as in LE
(1)
. 
 
 
 
 
Lichen planus pemphigoides: 
In this rare variant, there is an acute onset of generalized lesions of 
LP followed by the appearance of tense vesicles and bullae on and around 
those lesions as well as on uninvolved normal looking or erythematous 
skin. Extremities are usually involved. Oral lesions are rare. It can be 
differentiated from bullous LP, where vesicles appear only on and around 
lichen planus lesions for a brief duration
(1)
. 
Keratosis Lichenoides Chronica (Nekam’s Disease): 
It is a rare dermatosis characterized by violaceous papular and 
nodular lesions,  arranged in a linear and reticulate pattern on the dorsum 
of hands and feet, extremities and buttocks
(1)(8)
.  
Lichen Planus and Malignant Transformation: 
Malignant transformation of oral lichen planus is controversial.  
Risk factors for development of oral cancer in LP are long-standing 
disease, erosive or atrophic types and tobacco use. Only 0.5-5% of 
patients develops squamous cell carcinoma.  The most common site for 
malignant change is the tongue, followed by buccal mucosa, gingiva and 
rarely the lips. The lesions appear as indurated, non-healing ulcers or 
exophytic lesions with a keratotic surface
(1)(8)
. 
 
 
 
Lichenoid Reaction of Graft-Versus-Host Disease (GVHD): 
It may present as lichenoid eruptions over the trunk, buttocks, hips, 
thighs, palms, and soles. In oral mucosa, xerostomia and oral ulcerations 
are occasionally seen. Histologically, infiltrating CD3 + T lymphocytes 
are present in larger number in oral LP than in lichenoid lesions of oral 
GVHD
(1)(8)
. 
Lichenoid Keratosis: 
 It is commonly seen on sun-exposed areas of the extremities. 
Clinically presents as brown to red, scaling maculo-papules. Histology 
shows features of lichen planus with additional features of focal 
parakeratosis. 
 
ASSOCIATED CONDITIONS: Idiopathic Lichen planus has been 
reported to be associated with disease of altered immunity
(8)
. 
 Alopecia areata 
 Vitiligo 
 Morphea 
 Dermatomyositis 
 Systemic lupus erythematosus 
 
 
 
 Lichen sclerosus et atrophicus 
 Pemphigus vulgaris 
 Paraneoplastic pemphigus 
In association with thymoma: 
 Myasthenia gravis 
With gastrointestinal diseases: 
 Primary sclerosing cholangitis 
 Primary biliary cirrhosis 
 Ulcerative colitis 
 Chronic hepatitis 
LP has also been associated with Diabetes mellitus, Hypertension. 
 
Association with HCV: 
 The prevalence of HCV infection in lichen planus has been 
reported to be 3.4% to 38%
51
, and that with oral lichen planus is 0% to 
62%. In HCV infected individuals the association with oral LP is 1.6% to 
20%
(52)
. 
 
 
 
 
Syndromes associated with LP: 
 Grinspan’s Syndrome(35): Association of Oral LP with diabetes 
mellitus and hypertension. 
 Graham-Little-Piccardi-Lasseur Syndrome(1)(54): It is a triad of 
multifocal cicatricial alopecia of scalp with non-cicatricial alopecia of 
axilla and groin with follicular LP on the body, scalp or both. 
 Good’s Syndrome(40): Oral erosive lichen planus associated with 
Thymoma. 
 Jolly in 1972 found a defect in carbohydrate tolerance in oral LP 
cases
(36)
. 
 Lichen planus as a part of Multiple Auto immune Syndrome. 
 Turner’s Syndrome with LP 
 Polyglandular Auto-immune Syndrome type II with Oral LP 
 Lichen planus with Vulvo-vaginal-gingival Syndrome(41). 
 Ulcerative LP with Sjogren’s Syndrome. 
HISTOPATHOLOGY OF LICHEN PLANUS
(6)(18)
 
 Compact orthokeratosis   
 Wedge shaped hypergranulosis 
 Vacuolar alteration of the basal layer 
 
 
 
 Band-like dermal lymphocytic infiltrate in close approximation to 
the epidermis. 
The earliest finding is an increase in epidermal Langerhans cells, 
associated with a superficial infiltrate of lymphocytes and histiocytes, 
impinging on the dermo-epidermal junction [DEJ]. Mild spongiosis 
followed by vacuolar alteration, clefting along the dermal-epidermal 
junction, with accumulation of necrotic keratinocytes [colloid bodies].
(18)
 
Hyperkeratosis: The cornified layer shows compact orthokeratosis and 
contains few parakeratotic cells,which are important for diagnosis.
(18) 
Focal hypergranulosis: The thickening of granular layer is uneven and 
wedge shaped. The granular cells appear increased in size and contain 
coarse and abundant keratohyaline granules.
(18)
 
Acanthosis:  It is irregular and affects the spinous layer and 
suprapapillary plates. Keratinocytes of spinous layer appear larger and 
eosinophilic, possibly because of advanced keratinization. 
The rete ridges show irregular lengthening and some are pointed at lower 
end giving a saw-toothed appearance. 
Alteration of basal cell layer: The cells are not clearly visible in early 
lesions, because the dense dermal infiltrate obscures dermo-epidermal 
 
 
 
junction with vacuolar alteration and necrosis of these cells. In fully 
developed lesions, basal cells appear as flattened squamous cells
(18)
. 
Band-like dermal lymphocytic infiltrate: The infiltrate in the upper 
dermis is band-like and sharply demarcated at its lower border, 
comprising entirely of lymphocytes and macrophages . 
 Few eosinophils and or plasma cells may be seen. Melanophages 
are seen in upper dermis with subsequent pigment incontinence. 
Colloid bodies: Necrotic keratinocytes also referred to as colloid, 
hyaline, cytoid or civatte bodies are present in the lower epidermis and 
especially in papillary dermis. These are 20µ in diameter, homogenous, 
eosinophilic, and may occur in any interface dermatitis
(18)
. 
Max-Joseph Space:  They are small areas of artefactual separation 
between the epidermis and dermis. 
 
 
 
 
 
 
 
Variations of LP-histopathology: 
Hypertrophic LP: Epidermis shows irregular acanthosis, papillomatosis 
and hyperkeratosis. In the center of the lesion the follicles may be 
expanded and at times have a “cyst-like” appearance. Long standing 
cases will be dermal fibrosis adjacent to the inflammatory changes
(6)(18)
. 
Atrophic LP: The epidermis may be greatly thinned almost to the level 
of granular layer, although relative compact hyperkeratosis remains. The 
rete ridges are usually completely effaced with relatively few colloid 
bodies. The papillary dermis shows fibrosis. 
Lichen Planopilaris: Infiltrate extending around, and may permeate the 
base of the hair follicle epithelium, with follicular keratin plugging
(6)(18)
. 
Actinic LP: Epidermis shows orthokeratosis and hypergranulosis. The 
prickle cell layer at the center of lesion is thin and atrophic with loss of 
rete pegs, at borders it is acanthotic with saw-tooth appearance. The 
upper dermis shows classical band of lymphocytic infiltrates hugging 
epidermis
(6)(18)
. 
Lichen planus pigmentosus:  It is similar to classical lichen planus, 
except for the stratum granulosum which looks normal and there is 
pigment incontinence that extends deep in to reticular dermis
(6)(18)
. 
 
 
 
In oral LP:  The classical diagnostic features of oral lichen planus 
include parakeratosis alternating with both types of keratinization with 
presence of granular layer.  The epithelium is often atrophic
(6)(18)
. 
ELECTRON MICROSCOPY
(6)(18)
: 
1. The basal keratinocytes with their desmosomes and 
hemidesmosomes, show degenerative changes. 
2. Tonofilaments are decreased in early lesions, increased in late 
lesion. 
3. The dermal infiltrate, on invading the epidermis causes damage to 
the lamina densa such as fragmentation. This may be followed by 
duplication and irregular folding of the lamina densa. The dermal 
infiltrate contains lymphocytes and macrophages. 
4. Necrotic keratinocytes or colloid bodies are located in papillary 
dermis. 
 
 
 
 
 
 
IMMUNOFLUORESCENCE
(6) 
In Lichen planus, fibrinogen deposition can be demonstrated by 
Direct Immunofluorescence(DIF) as shaggy deposits at dermo-epidermal 
junction. There are also granular deposits of IgM or linear deposits of C3 
or both IgG and C3 in basement membrane zone. Necrotic keratinocytes 
are seen by DIF in 87%.They stain mainly for IgM but also for IgG, IgA, 
C3 and fibrin
(6)(20)
. 
 In Lichen planopilaris, DIF shows deposits of IgM and or IgA, IgG 
and rarely C3 at the level of infundibulum and isthmus. The shaggy 
pattern of fibrinogen are seen around affected follicles
(18)
. 
 In Lichen planus pemphgoides, DIF of perilesional skin shows 
IgG, C3 arranged linearly along the basement membrane zone
(18)
. 
IMMUNOCYTOCHEMICAL STUDIES 
 The infiltrating cells in lichen planus are chiefly T lymphocytes 
with very few B lymphocytes. Around 90% are activated T lymphocytes 
expressing HLA-DR antigen and some interleukin-2 receptor. It is likely 
that both subsets participate in immunologic reaction in the epidermis 
adjacent to the infiltrate, basal keratinocytes express HLA-DR surface 
antigen and ICAM-1, both of which are implicated in the enhancement of 
 
 
 
the interaction between lymphocytes and their epidermal targets resulting 
in keratinocyte destruction. Probably these surface antigens are induced 
by cytokines released by lymphocytes from the infiltrate
(18)
. 
COMPLICATIONS 
Hair fall: Patches of atrophic cicatricial alopecia develop over the scalp. 
It results from follicular destruction by the inflammatory infiltrate with 
scarring
(1)(15)
. 
Pterygium unguis: Adhesion between the epidermis of the dorsal nail 
fold and the nail bed may cause partial destruction of the nail, rarely nail 
may be permanently lost
(1)(15)
. 
Malignant transformation: Risk of malignant transformation is very 
low. Risk factors for the development of oral cancer are long standing 
disease, erosive or atrophic lichen planus and use of tobacco.  There is a 
possibility of 0.5-5% of LP patients developing Squamous cell 
carcinoma. Risk of skin malignancy in cutaneous LP is very low
(1)(8)
. 
Erythroderma– Generalised lichen planus 
 
 
 
 
 
DIFFERENTIAL DIAGNOSIS: 
Lichenoid eruptions: The only differential diagnosis to be considered in 
classical LP is that of lichenoid eruptions. Lichenoid drug eruptions have 
been reported after ingestion, contact, inhalation of certain chemicals or 
drugs
(1)(8)
. These  reactions have also been described as a reflection of 
chronic graft-versus-host disease in patients after bone-marrow 
transplantation. Lichenoid eruptions may be typical or atypical for classic 
LP, with localized or generalized eczematous papules and plaques. The 
salient features of differentiation are as follows
(1)
 
 Classic LP Lichenoid 
eruptions 
Lesion Smaller  Larger and scaly  
Wickham’s striae Usually present  Usually absent 
Residual 
hyperpigmentation 
Possible Common  
Alopecia  Uncommon Common  
Predilection  Flexures/extremities  Sun-exposed areas 
Mucous membrane 
involvement  
Very common 
 
Less common  
Colloid bodies in 
granular layer 
Very common Common 
Parakeratosis Not seen  Common 
 
 
 
 
Papular lesions of LP should be differentiated from other papulo-
squamous lesions especially psoriasis
(1)(5)
.  
Annular lesions may resemble granuloma annulare
(1)
. 
Linear LP should be differentiated from nevus unius lateris, lichen 
striatus and epidermal nevus
(1)
.   
Hypertrophic LP may resemble lichen simplex chronicus, prurigo 
nodularis, lichen amyloidosis, warts and Kaposi sarcoma
(1)
. 
Atrophic LP may mimic lichen sclerosis et atrophicus. Follicular LP 
may resemble lichen nitidus and lichen spinulosus
(1)
. 
Lichen plano-pilaris should be differentiated from other causes of 
cicatricial alopecia such as lupus erythematosus, inflammatory folliculitis 
and cicatricial pemphigoid
(1)
. 
Nail involvement may resemble psoriasis, alopecia areata and 
onychomycosis. 
Oral lesions should be differentiated from candidiasis, lupus 
erythematosus and mucous patches of secondary syphilis, paraneoplastic 
pemphigus and oral pemphigus
(1)
. 
  
 
 
 
TREATMENT 
 Lichen planus is essentially a benign and self-limiting condition.  
Current treatment modalities consist of topical and systemic therapy for 
cutaneous lichen planus. 
TOPICAL SYSTEMIC 
PHOTO- 
THERAPY 
MISCELLANEOU
S 
Topical 
steroids 
Intralesional 
steroids 
Tacrolimus 
Pimecrolimus 
Psoralens 
Photochemo-
therapy 
 
 
 
 
1
st
 line: 
Systemic steroids 
Acitretin 
Etretinate 
Isotretinoin 
2
nd
 line: 
Cyclosporine 
Dapsone 
Azathioprine 
Hydroxychloroquine 
Mycophenolate 
mofetil 
PUVA 
NB-UVB 
Balneotherapy 
 
Doxycycline 
Tetracycline  
Nicotinamide 
Interferon alpha 2b 
Metronidazole 
Cyclophosphamide 
Methotrexate 
Griseofulvin 
Low molecular 
weight heparin 
 
 
  
 
 
 
Treatment of oral Lichen Planus: 
TOPICAL SYSTEMIC PHOTO- 
THERAPY 
MISCELLANEO
US 
1
st
 line: 
Topical steroids 
Intralesional steroids 
Lidocaine 
Tretinoin gel 
Isotretinoin gel 
Tacrolimus 
Pimecrolimus 
2
nd
 line: 
Cyclosporine mouth 
wash 
Extracorporeal 
photochemotherapy 
PDT 
1
st
line: 
Anti candidal drugs 
Systemic steroids 
Etretinate 
Isotretinoin 
Acitretin 
2
nd
 line: 
Cyclosporine 
Griseofulvin 
Azathioprine 
Thalidomide 
Cyclophosphamide 
Hydroxychloroquine 
Mycophenolate 
mofetil 
PUVA 
 
 
6-thioguanine 
Azathioprine 
Sulfasalazine 
Tacrolimus 
Pimecrolimus 
Photodynamic 
therapy 
Lasers-excimer 
(308nm) 
 
  
 
 
 
Corticosteroids : 
 Corticosteroids are the first line of treatment of LP. Depending on 
the extent of involvement and type of lesions steroids can be used as 
topical, systemic or intralesional forms
(1)
. 
Topical steroids: They can be used for limited cutaneous and mucosal 
disease. Potent topical preparations like Flucinonide 0.05% and 
Clobetasol propionate 0.05% under occlusion may cause regression of 
cutaneous lesions in most instances. Oral lesions can be treated with 
triamcinolone acetonide oral lozenges, betamethasone aerosols and 
pellets
(15)
. 
Systemic steroids: Indicated for
(15) 
1) Extensive lesions interfering with patient’s normal life 
2) Nail atrophy and pterygium formation 
3) LP with extensive ulcerative lesions on oral or vaginal mucosa 
4) Follicular LP of scalp 
5) Bullous LP. 
Prednisolone, methylprednisolone and triamcinolone have been used.  
 
 
 
The effective dose of prednisolone is 5 to 20 mg/day for 4 to 6 weeks and 
then gradually tapered for another 6 weeks
(15)
. 
Intralesional: Triamcinolone acetonide 5 to 20 mg/ml is used to treat 
hypertrophic, oral and nail LP. 
Retinoids:  
Topical retinoids: 0.1% Isotretinoin gel has shown to improve the 
lesions of oral LP, but relapses are common with discontinuation of the 
drug
(1)(8)
. 
Systemic retinoids: Acetretin in a dose of 30 mg/day for 8 weeks in 
severe cutaneous LP and 30-35 mg/day daily for 2 weeks in patients with 
LP and LE overlap syndrome
(22)
. Etretinate or isotretinoin 0.6-1 
mg/kg/day three times daily for 2 months. 
Photochemotherapy: Psoralen and ultraviolet A photochemotherapy is 
useful in generalized cutaneous LP and refractory erosive oral LP. 
Initial dose is 0.5 – 2 J/   . The maximum dose not to exceed 7 
J/    in a single session, treated 3 times per week with an interval of 
48hrs between each session
(1)(20)
. 
 
 
 
 
Immunosuppressive drugs: 
Cyclosporin A is used in recalcitrant LP in the dose of 3-10 mg/kg/day. 
Pruritus disappears in 1-2 weeks and rash disappears in 4-6 weeks
(1)(25)
. 
Tacrolimus 0.1% ointment improves refractory erosive oral LP. It is 
very effective in controlling the symptoms
(1)(26)
. 
Pimecrolimus 1% cream cleared oral LP in 4 weeks. 
Azathioprine is used in refractory generalized cutaneous LP and LP 
Pemphigoides
(1)
. 
Mycophenolate mofetil at a dose of 1500mg/day is used in oral, 
hypertrophic and bullous LP
(27)
. 
Miscellaneous: 
Antimalarials- Hydroxychloroquine 200 to 400mg/day is used in actinic 
LP and erosive LP
(1)
. 
Thalidomide-can be used in erosive LP refractory to other treatment. 
Dapsone- 200 mg/day is used in bullous and erosive LP for 4 – 6 weeks 
Phenytoin- 100 to 200 mg orally daily for 2 – 8 weeks in cutaneous and 
oral LP. 
 
 
 
Metronidazole- 500 mg orally twice daily for 1 to 2 months also 
reportedly clears the majority of cases of lichen planus
(28)
. 
IFN-α2b has been administered for the treatment of generalized lichen 
planus with improvement, but this biologic response modifier is also 
associated with exacerbation of LP. 
Surgery: Split thickness skin grafting has been used to cover ulcerative 
lichen planus of the feet that is recalcitrant to other treatments.
(1)(15) 
Course and prognosis: 
Lichen planus is an unpredictable disease that persists for one to 
two years, but may at times follow a chronic relapsing course for many 
years. The duration varies according to the morphology and extent of 
involvement of the lesions. Generalized lichen planus tend to regress 
faster than limited lesions. Spontaneous regression is often a uncommon 
feature of oral lichen planus. The mean duration for oral lichen planus 
averages about 5 years. 
Chances of conversion into malignancy is more so with oral LP. Relapse 
of the disease is common in 15 to 20 percent of the cases and tends to 
occur in same locations. Reccurences are more common in generalized 
 
 
 
lichen planus and tend to be of shorter duration. Hair loss is usually 
permanent
(1)(4)
. 
Low-Molecular weight Heparin
(11)
: 
Low-molecular weight Heparin is one among the optional 
treatments available for the management of cutaneous lichen planus. 
Mechanism of action: 
 Low dose of low-molecular weight heparin devoid of anti-
coagulant activity inhibits T lymphocytes heparanase enzyme activity, 
which is crucial in T cell migration to the target tissues
(11)
. 
 Enoxaparin has been proven to inhibit the expression of heparanase 
enzyme (endoglycosidase) that is synthesized by CD4 cells, allowing 
them to penetrate into subendothelial basal lamina of the epidermis by 
cleaving the heparin sulfate side chains of the extracellular matrix that is 
yet again crucial in the migration of the T-cells to the target tissues
(17)
. 
 Low doses of low molecular weight heparin also inhibit delayed 
type hypersensitivity responses. Sulfated disaccharides in the heparin 
moiety contribute to the immunomodulatory effect by inhibiting the 
cytokines mainly the TNF-α(33). 
 
 
 
 Enoxaparin is being widely used in the prevention and treatment of 
thromboembolic disorders. It does not affect the activated partial 
thromboplastin time and there is no significant microvascular bleeding 
when compared to conventional heparins. The recommended dose of 
enoxaparin in these conditions range from 20 to 80mg/day by 
subcutaneous injection. 
 It can be effectively used as a monotherapy in cutaneous lichen 
planus
(2)(11)
. It can lead to significant periods of remissions with 
consequent reduction in the relapse rates.  It’s anti-pruritic effect is 
evident within a week of onset of the treatment.  
 Enoxaparin was used for the first time in the treatment of Lichen 
planus in 1988 by Hodak et al.
(11)
 It was given at the dose of 3mg 
subcutaneously to 10 cases of LP. Regression of cutaneous lesions were 
observed with the disappearance of the itch. There was no improvement 
with the oral lesions. 
Enoxaparin sodium
(11)
: 
 Enoxaparin sodium is a low-molecular weight heparin. It is a 
sterile aqueous solution containing enoxaparin. The pH of the solution is 
 
 
 
5.5 to 7.5. It is obtained from the porcine intestinal mucosa by alkaline 
depolymerisation of heparin benzyl ester
(4)(11)
.  
MOA: It causes its effect by inhibition of factor Xa. It also has 
antithrombotic properties. 
Low-molecular heparin has a longer half-life, easier to use and 
more reliable than conventional heparins. Risk of heparin induced 
thrombocytopenia is lower.  
Other uses:  
1. Prophylaxis and treatment of deep vein thrombosis. 
2. Treatment of acute pulmonary embolism. 
3. Prophylaxis of ischemic complications of unstable angina. 
4. Prophylaxis of Non-Q-Wave Myocardial infarction 
5. Treatment of acute ST elevation Myocardial infarction. 
6. Patients undergoing abdominal surgery and Hip and Knee 
replacement surgery. 
Preparations: Enoxaparin sodium is available as- 
Prefilled syringes: 20 mg/0.2 ml, 30 mg/0.3 ml, 40 mg/0.4 ml 
Graduated prefilled syringes:60 mg/0.6 ml, 80 mg/0.8 ml,100 mg/1 ml. 
 
 
 
Dosage: Injection Enoxaparin sodium 4 mg given subcutaneously once 
weekly. Therapy is continued for nine weeks. 
Contraindications:   
1) Patients with renal impairment (creatinine clearance < 30 ml/min) 
2) Patients with active major bleeding. 
3) Patients with thrombocytopenia. 
4) Known hypersensitivity to enoxaparin sodium. 
5) Known hypersensitivity to heparin or pork products. 
6) Pregnancy Category B drug. 
7) Used with caution in elderly patients. 
 
PHARMACOLOGICAL PROPERTIES: 
Pharmacodynamic properties: Enoxaparin is a low molecular weight 
heparin with a high anti-Xa activity(100 I.U./mg), and with a low anti-IIa 
or antithrombin activity (28 I.U./mg).At doses required for the various 
indications, enoxaparin does not increase the bleeding time.  At 
 
 
 
preventive doses, enoxaparin causes no notable modification of APTT. It 
neither influences platelet aggregation nor binding of fibrinogen to 
platelets.   
Pharmacokinetic properties: The pharmacokinetic parameters have 
been studied in terms of the time course of plasma anti-Xa activity. 
Bioavailability: After subcutaneous injection, enoxaparin is rapidly and 
completely absorbed.  The bioavailability of the drug is close to 95%.  
Distribution: After subcutaneous injection, the maximum plasma activity 
is obtained three hours after the administration. The anti-X a activity is 
located in the vascular space. 
Biotransformation: Enoxaparin is primarily metabolized in the liver. 
Elimination: The elimination half-life of anti-Xa activity is 
approximately 4.4 hours after administration of 40 mg of enoxaparin and 
4 hours for an administration of 60 mg or 80 mg of enoxaparin. 
Excretion: Enoxaparin is eliminated in the urine. In the elderly, the 
elimination is slightly decreased. 
Dosage and method of administration: 1 mg (0.01 ml) of enoxaparin 
corresponds approximately to 100 anti-Xa I.U.  It should be injected by 
 
 
 
deep SUBCUTANEOUS ROUTE in prophylactic and curative treatment 
and by INTRAVASCULAR ROUTE during hemodialysis. 
Subcutaneous administration technique: The prefilled syringes are 
ready-to-use.  The air bubble from the syringe should not be expelled 
before the injection.  The SC injection should preferably be made when 
the patient is lying down. It is given in the anterolateral or posterolateral 
abdominal wall, alternately on the left and the right side. The injection 
itself consists in introducing the needle perpendicularly and not 
tangentially throughout its entire length into a fold of skin held between 
the thumb and the index finger.  The skin fold should be held throughout 
the injection. 
In generalized cutaneous lichen planus, a dose of 4 mg is given 
subcutaneously every week for nine weeks. 
Elderly: No dose adjustment is necessary in prophylactic therapy. Anti-
Xa activity measurement is done in cases of curative therapy. 
Children: Enoxaparin is not recommended for use in the children.  
Renal impairment: No dose changes needed at prophylactic therapy. 
Dose adjustment is mandatory at curative doses.  
 
 
 
 Enoxaparin should be used with extreme degree of caution in 
patients with history of heparin induced thrombocytopenia. 
This drug is inadvisable in the following situations: 
 Severe impaired renal functions 
 Hemorrhagic vascular cerebral stroke 
 Uncontrolled arterial hypertension 
  
 
 
 
Precautions for use: 
 If a significant decrease in platelet count occurs (30 to 50% of the 
initial   count), the drug should be discontinued. 
 Use with caution in hepatic or renal insufficiency. 
Drug interactions: 
 Acetylsalicylic acid  
 NSAID 
Undesirable effects: 
 Hemorrhage: This may occur during co-treatment with any 
anticoagulant. 
 Bluish marks at injection sites. 
 Localized or generalized allergic reactions. 
 Thrombocytopenia 
 Increased transaminase levels. 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES OF 
THE STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1)  To assess the efficacy of low molecular weight heparin in the 
management of Generalised cutaneous lichen planus. 
2).   To look for adverse effects of the drug during the treatment. 
3).  To assess the period of remission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
Place of study: Department of Dermatology, Government Stanley 
Medical College and Hospital, Chennai. 
Type of study: Randomized, Prospective, Open Label Study. 
Time duration: One year (July 2013 To June 2014) 
Sample size: 50 patients of Generalised cutaneous lichen planus. 
Study procedure: 
This study was conducted in accordance with the ethical committee 
approval obtained in June 2013 (Annexure 1). A brief and relevant 
medical history was taken at the initial visit and physical examination 
was done to ensure that all the relevant eligibility criteria (given below) 
are met. Informed and written consent was obtained (Annexure 3). 
Consent was also obtained for taking photograph of the patient during the 
study procedure and follow up. 
 Patients who satisfy the inclusion criteria (given below) and willing 
to take part in the trial were hospitalized and administered Inj. 
Enoxaparin Sodium 4 mg subcutaneously, every week for 9 weeks. Later 
patients were followed up for a period of 6 months. No antihistamines 
were used during this study period. 
 
 
 
Efficacy of the treatment is assessed by monitoring Itch Severity 
Score (ISS), DLQI and  reduction in number of old lesions and 
appearance of new lesions if any every 3 weeks during the study and 
monthly during the follow up for 6 months. Safety and tolerability is 
monitored by regular clinical examination and bi-weekly monitoring of 
relevant blood parameters. 
Skin biopsy was done in selected cases before and after the 
treatment to assess the histopathological response. 
 
INCLUSION CRITERIA 
 Patients with generalized cutaneous lichen planus.  
 Age > 20 years. 
 Patients selected with no history of any previous treatments. 
 Patients willing for follow up and to take photographs. 
 Patients with no contraindication to therapy with low 
molecular weight heparin. 
 
 
 
 
 
 
EXCLUSION CRITERIA 
 Known contraindications to heparin therapy. 
 Congenital or acquired haemostatic defects.  
 Uncontrolled hypertension.  
 Active peptic ulcer , recent stroke, liver and renal diseases. 
 History of drugs inducing lichenoid eruptions  
 Elderly and paediatric patients. 
 Pregnant and nursing mothers. 
 Patients with body weight < 50kg. 
 Patients on oral anticoagulants, platelet inhibitors. 
INVESTIGATIONS 
 Complete Blood Count (Including platelet count) 
 Coagulation Profile (PT with INR, APTT). 
 Renal and  Liver  Function Tests. 
 Stool occult blood tests. 
 HBV and HCV antibody tests. 
 ICTC, VDRL Tests. 
 Chest X-Ray, ECG. 
 Skin biopsy in selected cases. 
 
 
 
Withdrawal of patients was done under following conditions: 
       1. Request of the patient. 
      2.   Patient lost to follow up. 
      3.  Adverse event/reactions/intercurrent illness 
     `4.  Patients who develop signs and symptoms of hypersensitivity. 
 
CLINICAL EFFICACY PARAMETERS: 
Parameters monitored during each visit: 
1. Disappearance of itch in weeks after start of the treatment. 
2. Regression of skin lesions consistent with disappearance of itch. 
3. Nature of the old lesions – Grading of response to treatment by 
measurement of reduction in the extent of skin lesions. 
4. Appearance of any new lesions during the course of therapy and 6 
months after therapy. 
5. DLQI before and after the treatment. 
6. Adverse effects of the drug during the study period. 
7. Periodical monitoring of laboratory parameters. 
 
 
 
 
Assessment of clinical efficacy: The efficacy, safety and tolerability of 
Enoxaparin sodium is assessed by the following clinical parameters. 
 
1. Itch severity score (ISS): 
Grade ‘0’  -No itch 
Grade  ‘1’ -  Mild itch 
Grade  ‘2’ -  Moderate itch 
Grade  ‘3’ -  Severe itch 
Grade  ‘4’ -  Very severe itch 
Grade  ‘5’ -  Worst possible itch that interferes with daily activity. 
Itch severity score was assessed periodically every 3 weeks after the start 
of treatment along with nature of regression of the cutaneous lesions. 
2.      Dermatology life quality index (DLQI): 
0-1 :  No effect at all on patient’s life. 
2-5     :  Small effect on patient’s life. 
6-10   :  Moderate effect on patient’s life. 
11-20 :  Very large effect on patient’s life. 
21-30 :  Extremely large effect on patient’s life.  
 
 
 
Series of Questionnaire is used for assessment of DQLI. It includes  
1). Over the last week, how itchy was his/her skin. 
2).  How embarrassing is this skin condition to them. 
3).  How much has this skin disease interfered with their shopping or   
any leisure activities. 
4). Has this condition prevented them from working or studying. 
5).  Experiencing any problem with the partner and other family 
members. 
Responses interpreted as ‘Very much’, ‘A lot’, ‘A little’, ‘Not at 
all’ and ‘Not relevant’. Scoring is done based on these responses. 
3.  Grading of response to treatment by measuring reduction in 
skin lesions as follows: 
Grade 0 ( no response ) :  same number of lesions. 
Grade 1 ( mild response ) : less than one third of lesions reduction. 
Grade 2 ( moderate response ) : more than third and less than two thirds 
reduction. 
Grade 3 ( dramatic response ) : more than two third of lesion reduction. 
 
 
 
STATISTICAL ANALYSIS 
The collected data was analysed with SPSS 16.0 version. To 
describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and for 
continuous variables the mean and S.D were used. To find the 
significance difference between the bivariate samples in Paired 
groups Wilcoxon signed rank test was used & for Independent 
groups (Male & Female) Independent t test was used. For the 
multivariate analysis in repeated measures (ISS -Baseline & week 3, 
6 & 9) the Friedman test was used. To find the significance in 
categorical data Chi-Square test was used. In all the above statistical 
tools the probability value .05 is considered as significant level.  
 
P-Value  Highly Significant at P ≤ .01 
 
    P-Value  Significant at P ≤ .05 
 
    P-value Not Significant at P >.05 
 
 
 
                                                       
 
 
 
 
CLINICAL PHOTOS 
 
Classical Lichen Planus 
(Typical Violaceous Papule) 
 
 
Upper limb involvement 
 
 
 
 
 
 
 
Lower limb involvement  
 
 
Trunk Involvement 
 
 
 
 
 
 
 
 
 
Hypertrophic lichen planus 
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Palms and Soles 
 
                    
 
                   
  
 
 
 
 
Genital lichen planus 
 
              
 
             
 
  
 
 
 
 
Oral lichen planus 
                   
Reticular subtype 
 
                   
 
Lace-like white streaks on the buccal mucosa 
  
 
 
 
 
Oral lichen planus 
 
                   
Violaceous plaque on the tongue 
 
                
Violaceous plaque on the lower lip 
 
 
 
 
Nail changes 
Longitudinal striations 
           
 
Pterygium 
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HISTOPATHOLOGY OF LICHEN PLANUS 
Low power view 
 
 
 
 
  
Compact Hyperkeratosis 
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HISTOPATHOLOGY 
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CLINICAL PHOTOS 
Patient1                                   Before treatment 
 
 
 
 
  
 
 
 
 
Patient 1                                 After treatment 
 
 
 
 
 
  
 
 
 
 
Patient 2                         Before treatment 
 
                   
 
After treatment 
              
  
 
 
 
 
Patient 3                          Before treatment 
 
                  
 
After treatment 
                        
  
 
 
 
 
Patient 4                            Before treatment 
 
 
 
After treatment 
 
 
 
 
 
Histopathology of Lichen planus 
Before treatment 
 
After treatment 
 
 
 
Compact Hyperkeratosis 
Band like infiltrate at DEJ 
Thinned epidermis 
Decrease in infiltration at 
DEJ 
 
 
 
Patient 1-                           6 months after treatment 
 
                         
 
 
                          
  
 
 
 
 
 
Patient 2 -                     6 months after treatment 
 
 
 
 
                                 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
 
 
 
 
 
 
 
 
 
 
 
AGE DISRIBUTION 
 
 
 
 
 
 
AGE RANGE 
 
    Cumulative 
 Frequency Percent Valid Percent Percent 
     
Valid   20 TO 30 YRS 23 46.0 46.0 46.0 
31 TO 40 YRS 16 32.0 32.0 78.0 
41 TO 50 YRS 11 22.0 22.0 100.0 
Total 50 100.0 100.0  
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SEX DISTRIBUTION 
 
 
 
 
 
 
GENDER 
 
 
Frequency Percent Valid Percent 
Cumulative 
Percent   
      
 FEMALE 29 58.0 58.0 58.0 
 MALE 21 42.0 42.0     100.0 
 Total 50 100.0 100.0  
  
FEMALE, 29 
MALE, 21 
Gender Distribution 
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DURATION OF ILLNESS 
 
 
 
 
 
 
 
 
           
 
 
GROUP STATISTICS 
   
GENDER N Mean Std. Deviation 
Std. Error 
Mean 
 
 
      
Duration   FEMALE  29 6.59 1.323 .246 
 
MALE  21 6.76 1.411 .308 
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SYMPTOMS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISS 
 
 
  
Frequency Percent Valid Percent 
Cumulative 
Percent   
      
Valid 3 6 12.0 12.0 12.0 
 4 24 48.0 48.0 60.0 
 5 20 40.0 40.0 100.0 
 Total 50 100.0 100.0  
      
 
 
 
 
 
 
 
 
Alcoholic, 9 
Smokers, 12 Both, 21 
Stress, 4 
Risk Factors 
 
 
RISK FACTORS 
 
 
 
 
 
 
 
 
 
 
 
 
In this study,  
 
9 patients were alcoholic, 12 were smokers, among these 21 patients, 
5were smoker as well as alcoholic, 4 patients reported stress. 
  
 
 
 
Diabetic, 9 
Controlled Hpt, 
4 
Previous Medical History 
 
  
PREVIOUS MEDICAL HISTORY 
 
 
 
 
 
 
 
 
 
 
 
In this study,  
 
9 patients were diabetic with good glycemic status and 5 were with 
controlled hypertension on drugs. 
  
 
 
 
Oral Lesions, 14 
Reticular , 8 
Plaque, 4 
Erosive, 2 
ASSOCIATION WITH ORAL LESIONS 
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ASSOCIATION WITH ORAL LESIONS 
 
 
 
 
 
 
  
 
 
 
 
                      
 
Oral changes * GENDER 
 
 
CROSSTAB 
 
      GENDER    
             
      F   M  Total 
            
Oralchanges - Count   19  17 36 
   % within Oralchanges 52.8%  47.2%  100.0%  
   % within GENDER 65.5%  81.0%  72.0%  
             
  + Count   10  4 14 
   % within Oral changes 71.4%  28.6%  100.0%  
   % within GENDER 34.5%  19.0%  28.0%  
             
Total  Count   29  21 50 
   % within Oral changes 58.0%  42.0%  100.0%  
   % within GENDER 100.0%  100.0%  100.0%  
             
 
 
 
 
 
CHI-SQUARE TESTS 
 
  Value df 
Asymp. 
Sig.  
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig.  
(1-sided) 
Pearson Chi-
Square 
1.439
a
 1 .230     
Continuity 
Correction
b
 
.776 1 .378     
Likelihood Ratio 1.482 1 .223     
Fisher's Exact 
Test 
      .341 .190 
N of Valid 
Cases 
50         
 
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 
5.88 
 
b. Computed only for a 2x2 table. 
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ASSOCIATION WITH KOEBNERISATION 
 
 
 
  
 
 
 
 
KOEBNERISATION 
 
  
GENDER 
Total 
 
FEMALE MALE 
KP - Count 23 17 40 
% within 
GENDER 
79.3% 81.0% 80.0% 
+ Count 6 4 10 
% within 
GENDER 
20.7% 19.0% 20.0% 
Total Count 29 21 50 
% within 
GENDER 
100.0% 100.0% 100.0% 
 
 
 
Chi-Square Tests 
 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-
Square 
.021
a
 1 .886     
Continuity 
Correction
b
 
0.000 1 1.000     
Likelihood Ratio .021 1 .886     
Fisher's Exact 
Test 
      1.000 .589 
N of Valid Cases 50         
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.20. 
b. Computed only for a 2x2 table 
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ASSOCIATION WITH NAIL CHANGES 
 
 
 
 
 
 
 
  
  
 
 
 
 
Nail changes * GENDER 
 
Crosstab 
 
 
   GENDER  
      
   F M Total 
     
Nailchanges   - Count 28 16 44 
  % within Nailchanges 63.6% 36.4% 100.0% 
  % within GENDER 96.6% 76.2% 88.0% 
      
+ Count 1 5 6 
  % within Nailchanges 16.7% 83.3% 100.0% 
  % within GENDER 3.4% 23.8% 12.0% 
      
Total Count 29 21 50 
  % within Nailchanges 58.0% 42.0% 100.0% 
  % within GENDER 100.0% 100.0% 100.0% 
      
 
 
 
CHI-SQUARE TESTS 
 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. (1-
sided) 
Pearson Chi-
Square 
4.782
a
 1 .029     
Continuity 
Correction
b
 
3.048 1 .081     
Likelihood 
Ratio 
4.940 1 .026     
Fisher's Exact 
Test 
      .070 .041 
N of Valid 
Cases 
50         
 
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count 
is 2.52. 
 
b. Computed only for a 2x2 table. 
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DURATION OF REMISSION 
 
 
 
 
                             
 
  
 
 
 
 
 
Group Statistics 
 
 
GENDER N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Remission FEMALE 29 2.86 1.505 .280 
MALE 21 3.29 1.927 .421 
 
 
Independent samples test 
  
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. T df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
Remission Equal 
variances 
assumed 
1.904 .174 -.873 48 .387 -.424 .485 -1.400 .552 
Equal 
variances 
not 
assumed 
    -.839 36.488 .407 -.424 .505 -1.447 .600 
 
 
 
 
 
 
 
 
 
 
 
ITCH SEVERITY SCORE (ISS) 
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STATUS * WEEKS Cross tabulation 
 
 
    WEEKS   
   BASELINE 3RD WEEK 6TH WEEK 9TH WEEK Total 
 NO ITCH Count 0 0 16 33 49 
  % within STATUS 0.0% 0.0% 32.7% 67.3% 100.0% 
  % within WEEKS 0.0% 0.0% 32.0% 66.0% 24.5% 
MILD ITCH Count 0 2 11 5 18 
  % within STATUS 0.0% 11.1% 61.1% 27.8% 100.0% 
  % within WEEKS 0.0% 4.0% 22.0% 10.0% 9.0% 
MODERATE ITCH Count 0 24 16 10 50 
  % within STATUS 0.0% 48.0% 32.0% 20.0% 100.0% 
  % within WEEKS 0.0% 48.0% 32.0% 20.0% 25.0% 
SEVERE ITCH Count 6 18 6 2 32 
  % within STATUS 18.8% 56.2% 18.8% 6.2% 100.0% 
  % within WEEKS 12.0% 36.0% 12.0% 4.0% 16.0% 
VERY SEVERE ITCH Count 24 6 1 0 31 
  % within STATUS 77.4% 19.4% 3.2% 0.0% 100.0% 
  % within WEEKS 48.0% 12.0% 2.0% 0.0% 15.5% 
WORST POSSIBLE ITCH Count 20 0 0 0 20 
  % within STATUS 100.0% 0.0% 0.0% 0.0% 100.0% 
  % within WEEKS 40.0% 0.0% 0.0% 0.0% 10.0% 
Total Count 50 50 50 50 200 
  % within STATUS 25.0% 25.0% 25.0% 25.0% 100.0% 
  % within WEEKS 100.0% 100.0% 100.0% 100.0% 100.0% 
 
 
 
 
Chi-Square Tests 
 
 
  Value Df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 226.786
a
 15 .000 
Likelihood Ratio 245.459 15 .000 
Linear-by-Linear 
Association 
137.319 1 .000 
N of Valid Cases 200     
 
4 cells (16.7%) have expected count less than 5. The minimum expected count is 4.504 cells 
(16.7%) have expected count less than 5. The minimum expected count is 4.50 
     
 
 
 
 
 
 
 
DERMATOLOGY LIFE QUALITY INDEX (DLQI) 
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DLQI SCORE * BA Cross tabulation 
 
 
 
           BA  
        BEFORE AFTER Total 
            
DLQISCORE NO EFFECT Count   0  18 18 
     % within DLQISCORE  0.0%  100.0% 100.0% 
     % within BA   0.0%  36.0% 18.0% 
  SMALL EFFECT Count   0  26 26 
     % within DLQISCORE  0.0%  100.0% 100.0% 
     % within BA   0.0%  52.0% 26.0% 
  MODERATE EFFECT Count   37  6 43 
     % within DLQISCORE  86.0%  14.0% 100.0% 
     % within BA   74.0%  12.0% 43.0% 
  VERY LARGE EFFECT Count   13  0 13 
     % within DLQISCORE  100.0%  0.0% 100.0% 
     % within BA   26.0%  0.0% 13.0% 
Total    Count   50  50 100 
     % within DLQISCORE  50.0%  50.0% 100.0% 
     % within BA   100.0%  100.0% 100.0% 
 
 
 
CHI-SQUARE TESTS 
 
  Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 79.349
a
 3 .000 
Likelihood Ratio 103.875 3 .000 
Linear-by-Linear 
Association 
64.016 1 .000 
N of Valid Cases 100     
 
a.0 cells (.0%) have expected count less than 5. The minimum expected count is 6.50. 
 
  
 
 
 
 
 
NATURE OF LESIONS DURING THERAPY 
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OLDLESIONS * WEEKS 
 
Crosstab 
 
 
 
 
         WEEKS   
       3RD WEEK 6TH WEEK 9TH WEEK Total 
OLDLESIONS  Gr0  Count    2 0 0 2 
   % within OLDLESIONS  100.0% 0.0% 0.0% 100.0% 
   % within WEEKS  4.0% 0.0% 0.0% 1.3% 
 Gr1  Count    13 2 0 15 
   % within OLDLESIONS  86.7% 13.3% 0.0% 100.0% 
   % within WEEKS  26.0% 4.0% 0.0% 10.0% 
 Gr2  Count    26 24 13 63 
   % within OLDLESIONS  41.3%  38.1% 20.6% 100.0% 
   % within WEEKS  52.0%  48.0% 26.0% 42.0% 
 Gr3  Count    9 24 37 70 
   % within OLDLESIONS  12.9% 34.3% 52.9% 100.0% 
   % within WEEKS  18.0% 48.0% 74.0% 46.7% 
            
Total  Count    50 50 50 150 
   % within OLDLESIONS  33.3% 33.3% 33.3% 100.0% 
   % within WEEKS  100.0% 100.0% 100.0% 100.0% 
            
  
 
       
 
 
 
 
 
 
  Value Df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 45.095
a
 6 .000 
Likelihood Ratio 48.940 6 .000 
N of Valid Cases 150     
 
 
a. 3 cells (25.0%) have expected count less than 5. The minimum expected count 
is .67 
 
 
 
  
 
 
 
 
 
NEW LESIONS DURING THERAPY 
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NEW LESIONS * WEEKS 
 
 
 
         WEEKS   
            
       
3RD 
WEEK 6TH WEEK 9TH WEEK Total 
           
NEWLESIONS  -  Count    46 43 46 135 
   
% within 
NEWLESIONS  34.1% 31.9% 34.1% 100.0% 
   % within WEEKS  92.0% 86.0% 92.0% 90.0% 
            
+ Count    4 7 4 15 
   
% within 
NEWLESIONS  26.7% 46.7% 26.7% 100.0% 
   % within WEEKS  8.0% 14.0% 8.0% 10.0% 
            
Total  Count    50 50 50 150 
   
% within 
NEWLESIONS  33.3% 33.3% 33.3% 100.0% 
   % within WEEKS  100.0% 100.0% 100.0% 100.0% 
            
 
 
 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson 
Chi-
Square 
1.333
a
 2 .513 
Likelihood 
Ratio 
1.275 2 .529 
N of Valid 
Cases 
150     
 
a. 0 cells (0.0%) have expected count less than 5. The minimum expected value is 5.00 
 
  
 
 
 
 
Frequency Table 
ISS 
 
     Cumulative 
  Frequency Percent Valid Percent Percent 
      
Valid 3 6 12.0 12.0 12.0 
 4 24 48.0 48.0 60.0 
 5 20 40.0 40.0 100.0 
 Total 50 100.0 100.0  
      
   
 
 
ISS3   
      
     Cumulative 
  Frequency Percent Valid Percent Percent 
      
Valid 1 2 4.0 4.0 4.0 
 2 24 48.0 48.0 52.0 
 3 18 36.0 36.0 88.0 
 4 6 12.0 12.0 100.0 
 Total 50 100.0 100.0  
      
   
 
 
ISS6   
      
     Cumulative 
  Frequency Percent Valid Percent Percent 
      
Valid 0 16 32.0 32.0 32.0 
 1 11 22.0 22.0 54.0 
 2 16 32.0 32.0 86.0 
 3 6 12.0 12.0 98.0 
 4 1 2.0 2.0 100.0 
 Total 50 100.0 100.0  
      
 
ISS9 
 
          Cumulative 
  Frequency  Percent  Valid Percent Percent 
            
 Valid   0   33 66.0 66.0  66.0 
 1   5 10.0 10.0  76.0 
 2   10 20.0 20.0  96.0 
 3   2 4.0 4.0  100.0 
 Total   50 100.0 100.0   
            
      
  
 
 
 
NPar Tests 
 
Wilcoxon Signed Ranks Test 
 
Ranks 
 
  N  Mean Rank Sum of Ranks 
 
       
ISS3 - ISS Negative Ranks  50
a
 25.50 1275.00 
 
 Positive Ranks  0b .00 .00  
 Ties  0c   
 
 Total  50   
 
   
50
d
 
   
ISS6 - ISS Negative Ranks  25.50 1275.00 
 
 Positive Ranks  0
e
 .00 .00 
 
 Ties  0
f
   
 
 Total  50   
 
   
50
g
 
   
ISS9 - ISS Negative Ranks  25.50 1275.00 
 
 Positive Ranks  0
h
 .00 .00 
 
 Ties  0
i
   
 
 Total  50   
 
   
37
j
 
   
ISS6 - ISS3 Negative Ranks  19.00 703.00 
 
 Positive Ranks  0
k
 .00 .00 
 
 Ties  13
l
   
 
 Total  50   
 
   
47
m
 
   
ISS9 - ISS3 Negative Ranks  24.00 1128.00 
 
 Positive Ranks  0
n
 .00 .00 
 
 Ties  3
o
   
 
 Total  50   
 
   
26
p
 
   
ISS9 - ISS6 Negative Ranks  18.54 482.00 
 
 Positive Ranks  7
q
 11.29 79.00 
 
 Ties  17
r
  
 
 Total  50   
 
       
 
 
a. ISS3 < ISS  
b. ISS3 > ISS  
c. ISS3 = ISS  
d. ISS6 < ISS  
e. ISS6 > ISS  
f.       ISS6 = ISS  
g. ISS9 < ISS  
h. ISS9 > ISS  
i.       ISS9 = ISS  
 
 
 
j. ISS6 < ISS3  
k. ISS6 > ISS3  
l. ISS6 = ISS3  
m. ISS9 < ISS3  
n. ISS9 > ISS3  
o. ISS9 = ISS3  
p. ISS9 < ISS6  
q. ISS9 > ISS6  
r. ISS9 = ISS6 
 
 
 
 
  
 
 
 
 
TEST STATISTICS 
 
 
  Z 
Asymp. Sig.  
(2-tailed) 
ISS3 – ISS -6.327
b
 .000 
ISS6 – ISS -6.217
b
 .000 
ISS9 – ISS -6.246
b
 .000 
ISS6 - ISS3 -5.436
b
 .000 
ISS9 - ISS3 -6.057
b
 .000 
ISS9 - ISS6 -3.703
b
 .000 
 
 
 
a. Wilcoxon Signed Ranks Test  
b. Based on positive ranks 
 
 
Based on the “P” value of Itch Severity Score (ISS), 
Dermatology Life Quality Index (DLQI) and Grading of regression 
of the old lesions, the study conducted was significant.  
 
 
 
  
 
 
 
 
 
 
            DISCUSSION 
 
 
 
 
 
 
 
 
 
Lichen planus is one of the common dermatological condition that can 
affect any age group and it affects both sexes equally
(43)(57)
. 
 Various studies have been done elsewhere assessing the efficacy of 
low molecular weight heparin in generalized cutaneous lichen planus. 
Most of these studies used 3 mg of Enoxaparin subcutaneously for a 
period between 6 to 20weeks. For ease of convenience and follow up in 
this study, Enoxaparin 4 mg (20mg/0.2ml)
(11)
was used for 9 weeks. 
 It is more common in people more than 30 years old, but in our 
study the common age group affected was between 20 – 40 yrs (78%) 
that was significantly higher than the study by Sehgal et al
(12)
 (46%) and 
Kacchawa etal
(47)
(47%). 
 There was a female preponderance in this study. M : F = 1.38 : 1, 
which correlated with the study by Lodi et al
(49)
 and Daramola et al
(50)
. 
Most of the cases included were with duration between 6 to 9 
months, the range is slightly greater than that reported by Sehgal et al
(12)
 
and Kacchawa et al
(47)
 study (2 to3 months). 
Itching was the major symptom in many cases ranging from ‘very 
severe itch’ (48%) to ‘worst possible itch’ (40%). 
 
 
 
Sehgal et al
(12)
 and Kachawwa et al
(47)
 described moderate to severe 
itching in 95.91% and 72.8% cases respectively. Fine et al
(48)
 opined that 
severity of pruritus depends with the extent of involvement of skin 
lesions. Diabetes mellitus was a significant association in this study 
(18%). 
Hypertension was reported by Naldi et al
(45)
  in 11.5% cases and 
Kachawwa et al
(47) 
in 2.4% of cases. Boyd et al
(46)
 and Naldi et al
(45)
 
reported diabetes mellitus in 1.6% and 4.9%cases respectively. 
Oral lesions were noticed in 34.5% and 19.0% of female and male 
patients respectively. Buccal mucosa was involved in majority of cases 
(90%) with reticular type in 57%, plaque type in 28.5% and erosive in 
14% .Sehgal et al
(12) 
reported oral LP in 12.2% cases with 89% over 
buccal mucosa, 12.5% on lips and 6.2% on tongue, reticulate type in 
89.6% and erosive type in22.9% cases that was higher compared to our 
study. 
Nail changes were significant in 23.8% and 3.4% of male and 
female patients respectively. Kachawwa et al
(47)
 also reported nail 
changes in 6.4% cases whereas Sehgal et al
(12)
reported absence of nail 
changes. 
 
 
 
All the patients included in the study completed their treatment in 9 
weeks.  
There was a significant reduction in Itch severity score from 68% 
within week 1 of  therapy to 22% in week 2 and another 10% in  week 3.  
In the study of Hodak et al
(43)
, in 1998 done on 10 cases of lichen 
planus treated with enoxaparin 3 mg did not observe improvement in only 
2 cases, with disappearance of itch in 60% in week 1 and 30% in week 2, 
that correlates  with our study. 
Onset of regression of cutaneous lesions noticed within 1 to 2 
weeks of disappearance of the itch which again correlates with the study 
by Hodak et al
(43)
. H. Pacheco
(62)
 in 2001, showed a significant 
improvement in 5 of 7 patients. 
Cutaneous lesions showed dramatic improvement (Grade 3) in 
74% and moderate improvement (Grade 2) in 26% of the patients studied, 
whereas in the study by Wisam Ali Ameen and Zena Saeed Alfadhily
(79)
 
reported in the medical journal of babylon showed dramatic reduction in 
VAS score (86.6%) and all grades of clinical improvement in 80% of the 
patients. 
 
 
 
There was complete disappearance of the itch in 66% of patients 
with 15 reporting mild to moderate itch at the end of 9 weeks and 5 cases 
with recurrence of itch during follow up. Hodak et al
(43)
 reported no 
recurrence of itch during the treatment or follow up except in one patient 
with itch 5 months later. 
There was also a improvement in DLQI in 80% of the cases in this 
study that is comparable to the study by Fariba Iraji et al
(80)
 that 
demonstrated 72% complete or partial remission with significant 
improvement in quality of life. 
Also in 1999, M.P. Stefanidou
(2)
conducted a study on18 patients 
with lichen planus where complete remission was achieved in 61% of 
patients, S.Akdeniz et al
(61)
 in 2005 reported 83% remission in a study 
with 24 patients. Here in this study it is significantly higher (90%). 
New lesions were relatively uncommon and seen in 26.7% at the 
end of 9 weeks of this study. Hodak et al
(43)
 reported no improvement in 
clinical lesions in 2 out of 10 cases that were studied.  
 
 
 
 
 
 
Oral lesions were relatively resistant to treatment possibly due to 
shorter duration of this study. 
There were no adverse effects noticed with Enoxaparin during the 
study thus highlighting it’s safety for clinical use in lichen planus. 
There are also case reports of patients with chronic and refractory 
lichen planus that responded only to low molecular weight heparin. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            CONCLUSION 
 
 
 
 
 
 
 
 
 
 
The study conducted at our institution revealed the following- 
 Lichen planus commonly affects younger individuals, most 
common in the age group between 20 to 40 years. 
 There is a significant female preponderance. 
 Itching was the major symptom among these patients. 
 Diabetes mellitus was a significant association in few patients. 
 Clinical improvement noticed in the form of decrease in Itch 
Severity Score (ISS) within 1 to 3 weeks of commencement of the 
drug. 
 Cutaneous lesions showed regression after 1to 2 weeks of 
disappearance of itch in 80%-90% of the cases. 
 Grade 3 (dramatic response) achieved in 74% and Grade 2 
(moderate response) in 26% of cases at the end of 9 weeks. 
 There was no evidence of occurrence of any new lesions during the 
course of treatment in 76% of the cases. 
 There was also improvement in DLQI in almost 80% of the 
patients. 
 
 
 
 During the follow up period, 4 patients developed a few papules 
that later regressed spontaneously. 
 There was complete disappearance of itch in 66% of the patients at 
the end of the study. 
 During follow-up, 5 patients noticed a recurrence of mild to 
moderate itch. 
 Lesions healed with post inflammatory hyperpigmentation. 
 There is a variable period of remission ranging from 1.5 to 6 
months in almost 90% of the treated individuals. 
 Oral lesions, palms and soles involvement were resistant to 
treatment. 
 The drug was safer with no significant adverse effects reported 
during the study period. 
 The rapid improvement and sustained remission seen in this study 
indicate that low molecular weight heparin could be a safe, 
effective and an alternative monotherapy in the management of 
generalized cutaneous lichen planus. 
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                                                 ANNEXURE 1 
GOVT. STANLEY MEDICAL COLLEGE AND HOSPITAL 
DEPARTMENT OF DERMATOLOGY 
                                         PROFORMA 
 
NAME:       AGE:   SEX: 
OCCUPATION/INCOME:    ADDRESS WITH  CONTACT 
       NO: 
CHIEF COMPLAINTS: 
 
H/O PRESENT ILLNESS: 
PAST HISTORY: 
FAMILY HISTORY: 
PERSONAL HISTORY: 
EXAMINATION: 
INVESTIGATIONS: 
 
COMPLETE BLOOD COUNT: 
RENAL PROFILE: 
PLATELET COUNT: 
LIVER PROFILE: 
 
 
 
COAGULATION PROFILE  (PT, INR, APTT). 
HBV, HCV ANTIBOBY TITRE  HIV, VDRL    
CHEST X-RAY, ECG   STOOL OCCULT BLOOD TESTS. 
SKIN BIOPSY                                            FOLLOW UP 
  
 
 
 
                            ANNEXURE 2 
                               CONSENT FORM 
Mr,/Mrs,/Miss: 
Age: 
Address: 
Phone: 
Name of the Procedure: 
I undersigned Mr,/Mrs,/Miss___________________________ have been explained 
regarding above said procedure in my regional language.  I am fully aware of the 
possible side effects and risks involved in this procedure.  I am also aware that this 
procedure may not always be successful and no guarantee can be made for successful 
outcome of the procedure. 
I have been informed that this procedure will be performed by  
Dr. N. Sudhakar 
I have also been explained that during this procedure if any complication arises, I may 
be given any emergency treatment best suitable without asking my prior permission. 
I further state that I have carefully read and understood all the information provided in 
this form and with full conscious mind I hereby give my consent for the said 
procedure with its risk involved. 
Signature of the patient/ right thumb impression: 
 
Witness: 
Name: 
Signature:         Date:   
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1. Vijaya 35 F 5mo - - - 5 Gen +/- 3 Gr3 - 2 Gr3 - 0 Gr3 - 6 2 2  1 - 
2. Rupchandran 22 M 6 mo + - - 5 Gen +/- 3 Gr1 - 3 Gr2 + 2 Gr2 - 8 4 2.5   3 - 
3. Jamaal 38 M 4mo - - RT 4 Gen +/- 3 Gr2 - 0 Gr3 - 0 Gr3 - 8 1 6   1 - 
4. Albert 24 M 6mo - PT - 3 Gen +/- 2 Gr2 - 0 Gr3 - 0 Gr3 - 9 2 6  1 - 
5. Gayathri 25 F 7 mo + - - 5 Gen +/- 3 Gr2 - 2 Gr2 + 2 Gr2 + 12 7 0  1 - 
6. Nawaz 23 M 6mo - - - 3 Gen +/- 2 Gr1 - 2 Gr2 - 0 Gr3 - 7 2 3  1 - 
7. Renukadevi 38 F 8 mo - - PL 4 Gen +/- 2 Gr2 - 2 Gr2 - 0 Gr2 - 10 4 3   1 - 
8. Velankanni 28 F 6mo - - - 3 Gen +/- 2 Gr3 - 0 Gr3 - 0 Gr3 - 9 1 4   1 - 
9. Balkis 25 F 7mo - - RT 5 Gen +/- 4 Gr1 + 3 Gr3 - 1 Gr3 - 11 5 2   2 - 
10. Balraj 46 M 5 mo - SK - 4 Gen +/- 2 Gr2 - 0 Gr2 - 0 Gr3 - 9 2 3  1 - 
11. Selvaraj 44 M 9mo - - - 4 Gen +/- 2 Gr1 - 2 Gr2 - 0 Gr3 - 8 2 2  1 - 
12. Hemchandra 20 M 7 mo + - - 4 Gen +/- 3 Gr2 - 1 Gr3 - 0 Gr3 - 9 1 6  1 - 
13. Kousalya 30 F 8mo - TL - 5 Gen +/- 4 Gr1 - 3 Gr2 - 0 Gr2 - 12 5 5   1 - 
14. Nagesh 45 M 7 mo + - - 5 Gen +/- 4 Gr0 + 4 Gr1 - 3 Gr2 - 17 6 2   3 - 
15. Nirmala 28 F 8mo - - - 5 Gen +/- 4 Gr2 - 2 Gr2 - 0 Gr2 - 9 4 2   1 - 
16. Thambiraj 22 M 6 mo - TL - 4 Gen +/- 3 Gr2 - 2 Gr3 + 0 Gr3 - 9 2 4 1 - 
17. Vanitha 35 F 5mo - - - 5 Gen +/- 3 Gr1 - 2 Gr2 - 0 Gr2 - 10 5 5  1 - 
18. Vijayalaxmi 37 F 8mo + - PL 4 Gen +/- 3 Gr3 - 0 Gr3 - 0 Gr3 - 6 1 3   1 - 
19. Srinivasan 37 M 9mo - SK - 5 Gen +/- 4 Gr0 - 3 Gr1 - 3 Gr2 - 18 8 1.5   2 - 
20. Ravi 25 M 7mo + - - 4 Gen +/- 2 Gr2 - 1 Gr3 - 0 Gr3 - 7 1 2.5   1 - 
21. Prehalya 21 F 6 mo - - - 3 Gen +/- 1 Gr3 - 1 Gr3 - 0 Gr3 - 8 1 4   1 - 
22. Arumugam 31 M 7mo - - RT 5 Gen +/- 3 Gr2 - 3 Gr2 - 2 Gr2 + 11 7 0 2 - 
23. Gomathi 40 F 5mo - - - 5 Gen +/- 4 Gr2 - 0 Gr2 - 0 Gr3 - 9 4 2.5   1 - 
24. Gowri 27 F 6mo - - - 4 Gen +/- 2 Gr1 - 1 Gr2 - 0 Gr3 - 8 2 1.5   2 - 
25. Bhagyalaxmi 26 F 5 mo + - - 5 Gen +/- 3 Gr2 - 2 Gr3 - 0 Gr3 - 10 4 5  1 - 
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26. Indirani 50 F 6 mo - - - 4 Gen +/- 2 Gr2 - 2 Gr2 - 0 Gr3 - 9 3 2  1 - 
27 Selvarani 21 F  7 mo - - - 5 Gen +/- 2 Gr1 - 0 Gr2 + 1 Gr3 - 9 4 2.5   3 - 
28  Ganesh  42 M  9 mo - - - 4 Gen +/- 2 Gr3 - 0 Gr3 - 0 Gr3 - 8 1 6   1 - 
29. Marthammal 38 F  8 mo - - ER 4 Gen +/- 2 Gr2 - 2 Gr2 + 2 Gr2 + 10 7 0  2 - 
30. Shanthi 46 F  6mo - - - 4 Gen +/- 2 Gr2 - 2 Gr3 - 0 Gr3 - 7 1 2.5   1 - 
31. Vasugi 42 F  5 mo + - - 5 Gen +/- 3 Gr2 - 2 Gr3 - 2 Gr3 - 9 1 3   2 - 
32. Mani  44 M  7 mo - - RT 4 Gen +/- 2 Gr3 - 0 Gr3 - 0 Gr3 - 8 1 3   1 - 
33. Senthil 41 M  6 mo - TL - 3 Gen +/- 2 Gr2 - 0 Gr2 - 0 Gr3 - 9 1 4   1 - 
34. Ramya 38 F  9 mo + - PL 4 Gen +/- 3 Gr1 - 1 Gr2 - 2 Gr3 - 14 5 2   2 - 
35. Urmila  26 F  6 mo - - RT 4 Gen +/- 2 Gr2 - 0 Gr3 - 0 Gr3 - 8 1 3  1 - 
36. Mohd. Riyaz 36 M  9 mo - - - 5 Gen +/- 3 Gr3 + 1 Gr3 - 2 Gr3 - 10 2 6  3 - 
37. Bhavani 23 F 5 mo - - RT 4 Gen +/- 2 Gr1 - 2 Gr3 - 0 Gr3 - 12 5 6  1 - 
38. Gajalakshmi 37 F  7 mo - - - 4 Gen +/- 2 Gr2 - 1 Gr3 - 0 Gr3 - 7 1 5   1 - 
39. Venkatesh 49 M 5mo - - - 5 Gen +/- 3 Gr2 - 1 Gr2 - 2 Gr2 - 11 4 2   3 - 
40 Jayalakshmi 20 F 6 mo - - - 4 Gen +/- 2 Gr2 - 1 Gr3 - 0 Gr3 - 8 1 2   1 - 
41. Devagi 45 F 7 mo - - RT 5 Gen +/- 2 Gr2 - 0 Gr2 - 1 Gr3 - 11 3 4  2 - 
42. Avinash 21 M 8 mo - - - 3 Gen +/- 1 Gr3 - 0 Gr3 + 1 Gr3 - 8 2 5  1 - 
43. Abdul  29 M  6mo - - - 4 Gen +/- 2 Gr2 - 0 Gr3 - 0 Gr3 - 7 1 3   1 - 
44. Kamaladevi 40 F  9 mo + - PL 4 Gen +/- 3 Gr1 - 1 Gr2 - 1 Gr3 - 9 2 1.5   2 - 
45. Karthika 24 F  8 mo - - - 5 Gen +/- 3 Gr1 - 2 Gr2 - 0 Gr2 - 11 4 2.5   1 - 
46. Ravikumar 37 M 6 mo - - - 4 Gen +/- 3 Gr2 - 3 Gr2 + 2 Gr2 + 11 8 0  1 - 
47. Kamatchi 23 F  8 mo - - RT 5 Gen +/- 2 Gr3 - 0 Gr3 - 0 Gr3 - 7 1 5 2 - 
48. Nagarani 40 F 5mo - - - 4 Gen +/- 3 Gr2 - 1 Gr2 - 0 Gr3 - 8 1 2.5   1 - 
49. Vijayakumar 40 M  7 mo - - ER 5 Gen +/- 2 Gr1 - 0 Gr2 - 2 Gr3 - 12 5 1.5   2 - 
50. Suguna 24  F 5 mo - - - 4 Gen +/- 2 Gr2 + 2 Gr3 - 0 Gr3 - 7 1 2.5   1 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          KEY TO MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
 
SEX 
M -   Male 
F  -   Female 
 
DURATION: 
mo -   months 
 
KP – KOEBNERISATION 
+      Present 
-       Absent 
 
NAIL CHANGES 
TL  -    Thinning and Longitudinal ridging 
 SK  -   Subungual hyperkeratosis 
PT    -   Pterygium 
 
 
 
 
 
 
 
 
ORAL CHANGES 
RT  –     Reticular type 
PL  –     Plaque type 
ER  –     Erosive type 
 
ISS – ITCH SEVERITY SCORE 
Grade 5 -   Worst possible itch 
Grade 4 -   Very severe itch 
Grade 3 -   Severe itch 
Grade 2 -  Moderate itch 
Grade 1 -   Mild itch 
Grade 0- No itch. 
 
GRADING OF SKIN LESIONS: 
Grade 0 (no response):    Same number of lesions. 
Grade 1 (mild response):    Less than one third of lesions reduction. 
Grade 2 (moderate response):    More than third and less than two thirds 
reduction. 
Grade 3 (dramatic response):    More than two third of lesion reduction. 
 
 
 
 
 
DLQI – DERMATOLOGY LIFE QUALITY INDEX 
0 –  1 =    No effect at all on the patient’s life 
2 – 5 =   Small effect on the patient’s life 
6 – 10 = Moderate effect on the patient’s life 
11 – 20 = Very large effect on the patient’s life 
21 – 30 =  Extremely large effect on the patient’s life. 
NEW LESIONS: 
     +  Present  
-  Absent   
 
IMPROVEMENT OF LESION IN WEEKS: 
Week 1:  Regression of skin lesions within a week of disappearance of 
itch. 
Week 2:  Regression of skin lesions within two weeks of 
disappearance of itch. 
Week 3:  Regression of skin lesions within three weeks of 
disappearance of itch. 
 
ADVERSE EFFECTS: 
    No significant adverse effects observed. 
